Ezrin is a cytoplasmic linker molecule between plasma membrane components and the actin-containing cytoskeleton. We studied whether ezrin is associated with intercellular adhesion molecule (ICAM)-1, -2, and -3. In transfected cells, ICAM-1 and ICAM-2 colocalized with ezrin in microvillar projections, whereas an ICAM-1 construct attached to cell membrane via a glycophosphatidylinositol anchor was uniformly distributed on the cell surface. An interaction of ICAM-2 and ezrin was seen by affinity precipitation, microtiter binding assay, coimmunoprecipitation, and surface plasmon resonance methods. The calculated K D value was 3.3 ؋ 10 ؊7 M. Phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P 2 ) induced an interaction of ezrin and ICAM-1 and enhanced the interaction of ezrin and ICAM-2, but ICAM-3 did not bind ezrin even in the presence of PtdIns(4,5)P 2 . PtdIns(4,5)P 2 was shown to bind to cytoplasmic tails of ICAM-1 and ICAM-2, which are the first adhesion proteins demonstrated to interact with PtdIns(4,5)P 2 . The results indicate an interaction of ezrin with ICAM-1 and ICAM-2 and suggest a regulatory role of phosphoinositide signaling pathways in regulation of ICAM-ezrin interaction.
COS-1 cells were transfected with ICAM-1 cDNA subcloned into CDM8 expression vector (33) or with a construct that replaces the transmembrane and cytoplasmic domains with a glycophosphatidylinositol (GPI) anchor (25) . Transfections were performed with the DEAE-dextran method as described (34) . Chinese hamster ovary cells stably expressing ICAM-2 (35) were transfected with full-length ezrin cDNA expression vector (27) using LipofectAMINE (Life Technologies, Inc.). The CDM8 expression vector alone was used as a control for transfections. The transfected cells were grown on glass coverslips for 48 h before fixation with 3.5% paraformaldehyde in PBS at 4°C for 10 min. The monoclonal antibodies were used at 10 g/ml in PBS. After washes with PBS, the coverslips were reacted with fluorescein isothiocyanate-conjugated goat F(abЈ) 2 anti-mouse IgG (Immunotech, Marseille, France). The cells were then permeabilized with 0.1% Triton X-100 in PBS, stained with rabbit antiserum against ezrin (1:50) or a control serum followed by staining with tetramethylrhodamine isothiocyanate-conjugated goat F(abЈ) 2 anti-rabbit IgG (1:40) (Cappel, Durham, NC). The coverslips were viewed with a Zeiss epifluorescence microscope (Carl Zeiss, Thornwood, NY).
Peptide Synthesis and Immobilization-Three peptides of the following sequences were synthesized: IC1 peptide, RQRKI KKYRLQQAQKGTPMKPNTQATPP; IC2 peptide, QHLRQQRMGTYG-VRAAWRRLPQAFRP; and IC3 peptide, REHQRSGSYHVREEST-YLPLTSMQPTEAMGEEPSRAE, encompassing the predicted cytoplasmic domains of ICAM-1, ICAM-2, and ICAM-3, respectively. For microtiter well binding assays, the IC1 and IC3 peptide were biotinylated at the NH 2 terminus via a six-carbon spacer. In surface plasmon resonance (SPR) studies, IC2 peptide was replaced by the peptide ICK2, in which the NH 2 -terminal glutamine of IC2 was deleted and histidine replaced by lysine. The peptides were synthesized by Fmoc (N-(9-fluorenyl)methoxycarbonyl) chemistry on a SMPS 350 multiple peptide synthesizer (Zinsser Analytic, Frankfurt, Germany). The IC1, IC2, and IC3 peptides were coupled to CNBr-activated Sepharose 4B (Pharmacia Biotech, Uppsala, Sweden) at a concentration of 2 mg/ml according to the protocol provided by the manufacturer. The coupling efficiency was 93-99%.
Purification of Placental and Recombinant Proteins-The purification of placental ezrin was done essentially as described in Ref. 36 . The baculovirus ezrin expression construct was a kind gift of P. Mangeat (Université Montpellier II, Montpellier, France) and is described in Ref. 37 . Recombinant ezrin was purified as described in (13) . The vinculin PtdIns(4,5)P 2 binding glutathione S-transferase fusion construct, kindly provided by D. Critchley (University of Leicester, Leicester, United Kingdom), and its purification is described in Refs. 38 and 39. The glutathione S-transferase domain of recombinant vinculin was cleaved off by thrombin.
Affinity Chromatography and Affinity Precipitation Assays-The ICAM-1 and ICAM-3 peptides were coupled to Sepharose beads, and placental lysate was passed through the peptide-Sepharose column as described in detail in Ref. 25 . For affinity precipitation, 2 g of placental ezrin was incubated in the presence or absence of lipids (50 g/ml) in HKE buffer (20 mM HEPES, pH 7.4, 130 mM KCl, 0.2 mM EGTA) for 30 min at room temperature. 30 l of peptide-Sepharose 1:1 slurry was added, and the mixture was shaken for 2 h. The beads were pelleted, the supernatant removed and the beads washed in HKE buffer. Bound proteins were eluted from the beads by boiling in Laemmli sample buffer and analyzed in 8% SDS-PAGE gels stained with Coomassie Blue.
Enzyme-linked Immunosorbent Binding Assay-Biotin-conjugated ICAM-peptides were coated onto streptavidin-linked microtiter wells (Labsystems, Helsinki, Finland) at a concentration of 0.01 mg/ml in PBS. The wells were blocked with 2% bovine serum albumin in PBS for 2 h at 37°C. Recombinant ezrin (500 ng) was incubated with lipids (10 g/ml) under nitrogen in HKE buffer at room temperature for 30 min. The ezrin/lipid mixture was allowed to react with the peptides in microtiter wells for 2 h at room temperature in a plate shaker. The wells were washed extensively with HKT (20 mM HEPES, pH 7.4, 130 mM KCl, 0.05% Tween 20) buffer and incubated with the primary antibody, mAb 3C12 at 1:6000 dilution in HKT, and the secondary antibody, rabbit horseradish peroxidase-conjugated anti-mouse (Dako, Copenhagen, Denmark), 1:3000 dilution, for 1 h each. After washes, the substrate reaction was performed with o-phenylenediamine dihydrochloride (Sigma) and the absorbances were measured by Multiscan Mcc/340 (Labsystems) at the wavelength of 492 nm. Specific values were calculated by subtracting the background absorbance values (Ͻ0.05 absorbance units) from the total values. For inhibition assays, a dilution series of soluble, non-biotinylated IC1 peptide was added to the reaction mixture containing ezrin and PtdIns(4,5)P 2 .
Ezrin and ICAM Fusion Protein Constructs and the Coimmunoprecipitation Assay of Yeast Lysates-The cDNAs encoding the cytoplasmic domains of ICAM-1 (amino acids 478 -505) and ICAM-2 (amino acids 229 -254) or amino-and carboxyl-terminal domains (amino acids 1-309 and 278 -585, respectively) of ezrin were introduced to the pEG202 yeast expression vector, which contains a LexA binding site (40) . The same ICAM-cDNAs and the full-length ezrin cDNA were introduced to the pJG4 -5 yeast expression vector, which contains the HA epitope tag (41) . The sequences of all constructs were verified by sequencing. BOY yeast cells cotransformed with the EG202 fusion construct and the JG4 -5 fusion construct were grown overnight at 30°C, washed once with PBS, and lysed by vortexing in the presence of 1 ml of acid-washed glass beads (Sigma) in 0.5 ml of ELB buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 5 mM EDTA) supplemented with 1% Nonidet P-40 and protease inhibitors. The debris was removed by centrifugation, and the supernatant diluted with ELB plus 0.1% Nonidet P-40 to a final Nonidet P-40 concentration of 0.5%. The protein concentration was measured at A 280 nm. 250 g of total protein lysate was incubated in the presence or absence of 5 g/ml PtdIns(4,5)P 2 for 20 min at room temperature. The 12CA5 (anti-HA) antibody was added at a dilution of 1:1000 and incubated for 30 min on ice, followed by a protein ASepharose bead incubation for 2 h. After washes with ELB and 0.1% Nonidet P-40, the bound proteins were eluted by boiling in Laemmli sample buffer, and analyzed by subsequent SDS-PAGE and immunoblotting.
Immunoblot Analysis-The samples were separated by 10% SDS-PAGE, blotted onto nitrocellulose sheets, and blocked overnight using 5% nonfat milk powder in PBS plus 0.1% Tween 20. Primary antibodies were incubated for 1 h. Anti-LexA antibody was diluted 1:5000 and 12CA5 mAb 1:1500 in PBS plus 0.1% Tween 20. As secondary antibodies, either sheep peroxidase-conjugated anti-rabbit IgG or sheep peroxidase-conjugated anti-mouse IgG (Boehringer Mannheim GmbH, Mannheim, Germany) was used at a 1:1500 dilution for 30 min. The bound antibodies were detected by enhanced chemiluminescence (Boehringer). The comparison of the immunoprecipitates was done by densitometric analysis option of NIH Image program.
SPR Assays-Real-time analysis of the binding between ezrin and ICAM-peptides was performed with a BIAcore 1000 (BIAcore AB, Uppsala, Sweden). Peptides were immobilized on a sensor chip according to the manufacturer's protocol using the Amine Coupling Kit (BIAcore AB). ICAM-1 and ICAM-2 peptides (IC1 and ICK2) were diluted in 10 mM phosphate buffer (pH 7.0), and ICAM-3 peptide (IC3) was diluted in 10 mM acetate buffer (pH 4.0) to 200 g/ml. The resonance units (RUs) for immobilized ICAM-1, ICAM-2, and ICAM-3 peptides were 2300, 2500, and 1800 RU, respectively. Ezrin was diluted in the running buffer (HKE) to 2.9 M, and the solution was run over the peptide surfaces in the absence and presence of 9 M PtdIns(4,5)P 2 micelles or 100 g/ml mixed vesicles. Typically, the lipids were sonicated and preincubated with ezrin for 30 min at room temperature. In some experiments, the preincubation was omitted and PtdIns(4,5)P 2 (4.5 M) was first injected over the peptide surface, followed by an injection of ezrin, vinculin fragment, or bovine serum albumin (1.45 M). All samples were run over a control surface (activated and blocked surface). The measurements were performed at 25°C under a constant flow of 5 l/min. Kinetic constants for the interaction between the ICAM-2 peptide and ezrin were determined by immobilizing 1224 RU of the peptide on the sensor surface and injecting 2.9 M ezrin with the flow rate of 15 l/min at 25°C over the ICAM-2 peptide surface. The apparent association rate (k a ) and dissociation rate (k d ) constants for the interaction were determined from three parallel runs, and the data were analyzed according to a 1:1 interaction model using the BIAevaluation 2.1 software supplied by the manufacturer. The apparent dissociation constant (K D ) was calculated from the ratio k d / k a .
RESULTS

Colocalization of Ezrin, ICAM-1, and ICAM-2-Earlier
studies have shown that transfection of ezrin into thymoma cells redistributes ICAM-2 on the cell surface and renders them sensitive for killer cell lysis (27) . Ezrin also colocalizes with ICAM-2 in these cells, suggesting an interaction between the proteins. To extend the colocalization studies, we transfected wild type ICAM-1, and an engineered ICAM-1 form in which the cytoplasmic and transmembrane region is replaced with a GPI anchor, to COS-1 cells and compared their distribution to ezrin by indirect immunofluorescence microscopy. Transfected ICAM-1-wt was concentrated in microvilli where it perfectly colocalized with endogenous ezrin (Fig. 1A) . In contrast, the ICAM-1-GPI construct, which is attached to the cell membrane via a lipid, showed no preferential localization but was uniformly distributed on the cell surface (Fig. 1A) . No apparent codistribution with ezrin was detected. We also analyzed the colocalization of transfected ezrin in adherent Chinese hamster ovary cells that stably express human ICAM-2. The colocalization of these proteins was high (Fig. 1B) , concentrating at microvillar structures.
Binding of Ezrin to ICAM Cytoplasmic Domain PeptidesWhen placental lysate was passed over a column containing ICAM-1 cytoplasmic peptide as an affinity matrix, only a few polypeptides were retained to the peptide beads. One of the most prominent proteins eluted from the column migrated at a molecular mass of 75 kDa and reacted with an ezrin-specific antiserum ( Fig. 2A) , indicating a linkage between ICAM-1 and ezrin. The eluate did not contain several other cytoskeletal components, talin, vinculin, and spectrin, which were immunoblotted as a control (data not shown) (25) . In a similar experiment, in which ICAM-3 cytoplasmic peptide was used instead of ICAM-1, the profile of the bound peptides was different ( Fig.  2A , lane 4 versus lane 1) and ezrin was not detected among the proteins eluted from the column.
To study whether a direct association exists between ezrin and ICAM-1, we purified placental ezrin and analyzed its binding to streptavidin-linked microtiter wells coated with biotinylated ICAM-1 peptide. ICAM-1 peptide bound a small amount of ezrin in the absence of phospholipids (Fig. 2B) . The binding was not affected when ezrin had been preincubated with PC or . After washes, bound ezrin was detected by an ezrin-specific antibody and a secondary, horseradish peroxidase-conjugated antibody followed by a colorimetric substrate reaction. C, inhibition of ezrin binding to ICAM-1 peptide-coated microtiter well in the presence of PtdIns(4,5)P 2 by soluble, non-biotinylated ICAM-1 peptide. The soluble peptide was added to the ezrin/lipid mixture in indicated amounts prior to reaction with the immobilized ICAM-1 peptide.
PS, but was markedly increased when ezrin had been preincubated with PtdIns(4,5)P 2 . The binding in the presence of PtdIns(4,5)P 2 was inhibited by soluble non-biotinylated ICAM-1 peptide in a concentration-dependent manner (Fig.  2C) . In contrast, ezrin did not bind the ICAM-3 cytoplasmic peptide in the presence or absence of phosphoinositides (Fig.  2B) .
Another peptide-based approach was used to study the interaction of ICAM-2 and ezrin and the effect of PtdIns(4,5)P 2 on ezrin association to both ICAM-1 and ICAM-2. Synthetic peptides encompassing the cytoplasmic domains of ICAM-1, -2 and -3 were coupled to Sepharose beads and incubated with ezrin in the presence or absence of PtdIns(4,5)P 2 or PC. In these experiments (Fig. 3B) purified ezrin bound to ICAM-2, but not to ICAM-1 peptide beads in the absence of phospholipids. PC did not affect the interaction, but incubation with PtdIns(4,5)P 2 induced ezrin binding to ICAM-1 and remarkably increased the interaction with ICAM-2. ICAM-3 cytoplasmic peptide did not bind ezrin even in the presence of PtdIns(4,5)P 2 . As a control, we purified recombinant PtdIns(4,5)P 2 -binding fragment (amino acids 881-1066) of vinculin (38, 39) , a cytoskeletal component of focal adhesions with no apparent cellular colocalization with ICAMs. The fragment was able to bind to PtdIns(4,5)P 2 -containing large multilamellar liposomes in a manner comparable with purified ezrin (Fig. 3A) . However, the recombinant vinculin did not bind to ICAM-peptide beads, and the presence of PtdIns(4,5)P 2 did not induce a significant binding to beads as compared with ezrin binding (Fig. 3C) .
A real-time analysis of the binding between ezrin and ICAM peptides was performed with the SPR-based method. The peptides were immobilized on sensor chips, and ezrin or ezrin/ PtdIns(4,5)P 2 mixture was run over the peptide-containing surfaces. Fig. 4 (A and B) shows overlaid sensorgrams in the absence and presence of added phospholipid, respectively. Analysis of the binding curves of several experiments indicated an interaction between immobilized ICAM-2 peptide and ezrin, whereas no binding to ICAM-1 and ICAM-3 peptides compared with the control surface (activated and blocked sensor chip) was observed. When ezrin was preincubated with micellar PtdIns(4,5)P 2 , it bound both to ICAM-1 and ICAM-2 peptides, but not to ICAM-3. Ezrin binding to ICAM-2 was enhanced by the presence of PtdIns (4,5 To study the possibility that ezrin was associating to ICAM-1 and ICAM-2 just via PtdIns(4,5)P 2 micellar aggregates, the SPR assays were performed also by preincubating ezrin with vesicles consisting of a neutral phospholipid PC as a carrier, mixed with 8% (molar fraction) of PS or PtdIns(4,5)P 2 . The interaction inducing effect of PtdIns(4,5)P 2 was retained under these conditions, whereas the PC/PS vesicles had no effect on ICAM-1-ezrin interaction (Fig. 4C) . SPR results confirmed the role of PtdIns(4,5)P 2 -containing vesicles also in enhancing ezrin binding to ICAM-2 (Fig. 4D) .
In sequential analyses, where PtdIns(4,5)P 2 was run over ICAM-1 and ICAM-2 peptide surfaces prior to ezrin, a significant increase in the resonance units was induced on both surfaces by PtdIns(4,5)P 2 alone (Fig. 5A) . This result suggested an interaction between the ICAMs and PtdIns(4,5)P 2 . In contrast, ICAM-3 peptide surface did not bind PtdIns(4,5)P 2 (data not shown). Binding of ezrin on the ICAM-1 or ICAM-2 peptide surfaces pretreated with PtdIns(4,5)P 2 was evident (Fig. 5A) . As an additional test for the specificity of PtdIns(4,5)P 2 effect, the recombinant PtdIns(4,5)P 2 -binding fragment of vinculin was injected over the surfaces. The vinculin fragment induced only a minor shift in resonance units when run over ICAM-1 (Fig. 5C ) or ICAM-2 (data not shown) peptide surfaces after injection of micellar PtdIns(4,5)P 2 . Bovine serum albumin bound neither surface after the PtdIns(4,5)P 2 treatment (data not shown).
Coimmunoprecipitation of Ezrin and ICAM Cytoplasmic Domains-We made fusion protein constructs containing the cytoplasmic domains of ICAM-1 or ICAM-2, and cotransfected them into yeast together with constructs expressing full-length or The liposomes were pelleted, and the proteins retaining in pellet (P) or supernatant (S) were visualized by Coomassie staining of SDS gels. B, the ICAM-1, ICAM-2, and ICAM-3 peptides (IC1, IC2, and IC3, respectively) were coupled to Sepharose beads and allowed to react with purified ezrin in the presence of indicated lipids. The supernatant was collected, the beads washed, and bound ezrin eluted by boiling in Laemmli buffer. Ezrin was detected by Coomassie staining of SDSpolyacrylamide gels. Ϫ, no lipids added; PIP 2 , PtdIns(4,5)P 2 . Supernatants from the peptide beads (representing unbound protein) contain one fourth of the total material. C, the ICAM-1 and ICAM-2 peptide Sepharose beads were reacted with vinculin PtdIns(4,5)P 2 binding fragment and bound protein detected as in B. The right lane shows the intensity of the input material in the gel. NH 2 -terminal or COOH-terminal fragments of ezrin (Fig. 6A) . All the constructs were expressed at expected molecular sizes as analyzed by immunoblotting (Fig. 6B) . The full-length ezrin fusion protein was immunoprecipitated and the presence of coimmunoprecipitating ICAM fusion products detected. A weak band of ICAM-1 and a stronger band of ICAM-2 fusion protein were detectable in ezrin immunoprecipitates. The effect of PtdIns(4,5)P 2 was analyzed by incubating identical lysates with PtdIns(4,5)P 2 before the coimmunoprecipitation. PtdIns(4,5)P 2 treatment resulted in a 40-fold increase in the amount of coimmunoprecipitated ICAM-1 and in an 8-fold increase of coimmunoprecipitated ICAM-2 as analyzed densitometrically. A control fusion protein, which lacked ICAM cytoplasmic domains, did not coimmunoprecipitate with ezrin constructs under any conditions (data not shown). When ICAM fusion construct were immunoprecipitated, the carboxyl-terminal ezrin fusion protein did not coimmunoprecipitate either in the presence or absence of PtdIns(4,5)P 2 . On the other hand, the amino-terminal fusion construct coimmunoprecipitated with both ICAMs, and the presence of PtdIns(4,5)P 2 caused a 4-fold enhancement of binding to ICAM-2, but did not affect binding to ICAM-1 (Fig. 6C ).
DISCUSSION
In this study, we report that the cytoplasmic domain of ICAM-2 interacts with ezrin. The interaction is highly facilitated by PtdIns(4,5)P 2 , and PtdIns(4,5)P 2 induces an interaction between ezrin and ICAM-1 but not ICAM-3. An association was first suggested by transfection studies, which showed a close codistribution of wild-type ICAM-1 or ICAM-2 and endogenous or cotransfected ezrin in adherent cells, and ICAM-2 and ezrin in thymoma cells (27) . An engineered ICAM-1 molecule linked to the membrane by a glycophospholipid anchor showed a diffuse staining pattern without microvillar colocalization, indicating the requirement of an intact intracellular domain of ICAM-1 for the specific surface distribution and codistribution with ezrin.
A direct interaction of purified ezrin and ICAM-2 was detected with several different methods (Sepharose bead affinity precipitation, microtiter binding assay, coimmunoprecipitation, and surface plasmon resonance). The apparent dissocia- FIG. 4 . Binding of ezrin to ICAM-1 and ICAM-2 peptides studied by surface plasmon resonance. ICAM-1, ICAM-2, and ICAM-3 cytoplasmic peptides (IC1, ICK2, and IC3, respectively) were immobilized on a sensor chip, and purified ezrin was injected on the peptide surfaces under a constant flow. A, overlaid sensorgrams of ICAM-1, ICAM-2, and ICAM-3 peptide surfaces and a control surface (activated and blocked sensor surface). Ezrin (2.9 M) was injected in the absence of PtdIns(4,5)P 2 . B, overlaid sensorgrams of ICAM-1, ICAM-2, and ICAM-3 peptide surfaces and a control surface. Ezrin was incubated with 9 M PtdIns(4,5)P 2 for 30 min at room temperature before the injections. C, overlaid sensorgrams of ICAM-1 peptide surface and a control. Ezrin was incubated for 30 min with lipid vesicles consisting of PC as a carrier mixed with 8% (molar fraction) PS or PtdIns(4,5)P 2 (PIP 2 ) before injection over ICAM-1 peptide. In control, ezrin preincubated with PC/PtdIns(4,5)P 2 was injected over control surface. The total lipid concentration was 100 g/ml. D, overlaid sensorgrams of ICAM-2 peptide surface as in C.
FIG. 5. Binding of PtdIns(4,5)P 2 to ICAM-1 and ICAM-2 cytoplasmic domains and comparison of ezrin and vinculin binding.
A, overlaid sensorgrams of sequential injections over ICAM-1, ICAM-2, and control surfaces. 4.5 M PtdIns(4,5)P 2 (PIP 2 ) was injected over sensorchip, followed by subsequent injection of 1.45 M ezrin. B, overlaid sensorgrams of ICAM-1 surface injected with 4.5 M PtdIns(4,5)P 2 , followed by subsequent injection of 1.45 M vinculin fragment (lower curve) or purified ezrin (upper curve). In control, PtdIns(4,5)P 2 and vinculin fragment were injected on a control surface. tion constant of 3.3 ϫ 10 Ϫ7 M is in line with the affinities of other membrane protein-cytoskeleton interactions. For instance, ␣-actinin was reported to bind to ␤ 1 -integrin cytoplasmic domain peptide with K D of 1.6 ϫ 10 Ϫ8 M (42) and protein 4.1 binds to the cytoplasmic domain of CD44 with K D value on the order of 10 Ϫ7 M (43), whereas moesin binding to CD44 was too weak for quantitation at physiological ionic strength (13) .
In contrast to ICAM-2, only a very weak binding of ezrin to ICAM-1 was seen in the microtiter and coimmunoprecipitation assays in the absence of PtdIns(4,5)P 2 . When placental lysate was passed through ICAM-1 peptide column, ezrin was one of the few proteins that were retained. The lysate apparently contained PtdIns(4,5)P 2 . With all different methods used, the interaction of ICAM-1 or -2 and ezrin was either induced or highly enhanced by PtdIns(4,5)P 2 . This is in analogy with the interaction between ezrin and the transmembrane adhesion protein CD44 (13) . The microtiter and SPR assays with phospholipid vesicles consisting of a neutral carrier lipid PC mixed with a small portion of PtdIns(4,5)P 2, resembling the natural composition of cellular membranes, showed that the binding is not just an aggregation of PtdIns(4,5)P 2 micelles to the peptides, but a specific effect. Another cytoskeleton-associated protein, vinculin, is regulated by PtdIns(4,5)P 2 (39, 44, 45) , but compared with ezrin the phosphoinositide binding fragment of vinculin did not show significant binding to ICAM peptide surfaces pretreated with PtdIns(4,5)P 2 . This result further emphasizes the specificity of ezrin binding to ICAM peptides in the presence of PtdIns(4,5)P 2 .
ICAM-3 did not bind ezrin even in the presence of added phospholipids. When T-cells produce cellular uropods in response to cytokines and cAMP, ICAM-3 is redistributed to the uropod region together with myosin, not with the actin-based cytoskeleton (46 -48) . Moesin has been shown to interact with ICAM-3 in polarized T-cells, and stimulation of T-cells redistributed ICAM-3 and moesin, but not ezrin to the formed uropods (48) . In these cells, the expression level of ICAM-1 is low. It is possible that ICAM adhesion molecules and ERM proteins, with partly overlapping and redundant functions, display variable combinations in different physiological and cellular environments. In the present study, we have not analyzed whether other ERM family members interact with ICAM-1 and ICAM-2 in a fashion similar to ezrin. Considering the high sequence homology and a similar binding ability to CD44 (13) , it is likely that radixin and moesin can also associate with ICAM-1 and -2.
The SPR measurements demonstrated that PtdIns(4,5)P 2 interacts with the cytoplasmic tails of ICAM-1 and ICAM-2. Previously, a variety of cytoplasmic polypeptides, particularly actin-binding proteins, have been shown to bind PtdIns(4,5)P 2 , and PtdIns(4,5)P 2 is an important modulator of the actin-containing cytoskeleton (28, 29) . However, ICAM-1 and ICAM-2 are the first adhesion proteins reported to interact with PtdIns(4,5)P 2 . The consensus binding sequences for PtdIns(4,5)P 2 binding are (K/R)XXXXKX(K/R)(K/R) or KXXXKXKK (49) , although other binding sequences exist. The binding of phosphoinositides is not simply electrostatic, but also secondary structure and hydrophobic segments are thought to be important (49 -52) . The cytoplasmic domains of ICAM-1 and ICAM-2 contain both basic and hydrophobic residues resembling the described PtdIns(4,5)P 2 binding sites, and in particular the juxtamembrane sequence of ICAM-1 is highly homologous with the PtdIns(4,5)P 2 binding consensus motif. ICAM-3 did not bind PtdIns(4,5)P 2 in SPR measurements, and its amino acid sequence also differs from the typical PtdIns(4,5)P 2 binding site pattern. The differences in sequences suggest that the cytoplasmic interactions of ICAM-3 are possibly not regulated the same way as the interactions of ICAM-1 and -2.
Phosphoinositides promote conformational changes of the peptides to which they are bound (52, 53) and may increase or stabilize the formation of higher form oligomers, as suggested in the dimerization of the protein kinase Akt (54) . PtdIns(4,5)P 2 is implicated in adhesion; it is needed for focal adhesion formation (45) , and the levels of PtdIns(4,5)P 2 are increased by integrin clustering, which activates cytoskeletonassociated PtdInsP kinase locally within focal adhesion complex (55) . It is tempting to speculate that increased phophoinositide levels caused by preadhesion signaling or by initial PtdIns(4,5)P 2 acts as a precursor for the secondary messenger molecules inositol trisphosphate and diacylglycerol and is one of the substrates of PI 3-kinase, but also has independent signaling properties. It can interact with a number of actinbinding proteins and thereby regulate actin polymerization (28) . Ezrin and other ERM proteins are effector molecules of the Rho signaling pathway (56) , which controls actin filament and focal adhesion assembly. Rho regulates also phosphatidylinositol 4-phosphate 5-kinase (57), suggesting that Rho could activate ezrin through the controlled synthesis of PtdIns(4,5)P 2 . Our studies together with the results from the binding of CD44 (13) indicate a role for PtdIns(4,5)P 2 in controlling the ability of ezrin to bind transmembrane proteins. The amino-terminal domain of ezrin has an exceptionally high affinity to the carboxyl-terminal part, and in an inactive conformation apparently masks the actin binding domain by intraor intermolecular association (10, 58) . The mechanism of ezrin activation is unknown but is speculated to involve phosphorylation or dimerization/oligomerization of the molecule (59, 60) . A PtdIns(4,5)P 2 binding site is contained in the NH 2 -terminal half of ezrin (12) , and PtdIns(4,5)P 2 binding could be an alternative or additional mechanism to modulate the conformation of ezrin through uncovering binding sites for F-actin and other interacting molecules. This type of regulation has been reported for vinculin, in which PtdIns(4,5)P 2 dissociates an intramolecular head-to-tail joining (44) rendering the masked talin and actin binding sites accessible, and exposing a phosphorylation site for protein kinase C (39, 45) . Our coimmunoprecipitation results support the concept that the binding site for transmembrane proteins is in the amino-terminal part of ezrin. The finding that PtdIns(4,5)P 2 enhances ICAM-2 binding also to the NH 2 -terminal fragment of ezrin shows a complex role for PtdIns(4,5)P 2 , possibly modulating ICAM-2 activity in addition to ezrin regulation.
Ezrin is a prominent constituent of microvilli and other cellular protrusions and the leading edge. It is located at cell membrane regions that primarily come into contact with other cells. Thus ezrin, as well as other ERM-members, serve as ideal cytoplasmic binding partners for adhesion molecules. The ability of ezrin to redistribute ICAM-2 (27) , and probably also ICAM-1, to microvilli or concentrated patches on uropod-like structures increases the accessibility of these molecules and could also increase their avidity by clustering (Fig. 7) . Concentration of ICAMs would benefit the cells during conjugation between lymphoid cells and their target cells, and during migration of lymphocytes through endothelium to tissues. An interaction between ezrin and ICAMs also facilitates post-binding events, as demonstrated by experiments in which relocalization of ICAM-2 to the uropod region after transfection of ezrin rendered target cells susceptible for NK cell killing (27) . A similar mechanism may be involved in killing of viral infected cells, when ezrin redistributes from the cytoplasm into newly formed microvilli (61) . The finding that PtdIns(4,5)P 2 can be sequestered into lateral domains in the membrane upon binding to specific proteins (62) raises the possibility that the interplay of all three components, ezrin, ICAM-1 or ICAM-2 and PtdIns(4,5)P 2 , is regulated by their local distribution. In this manner, the versatile interactions between adhesion molecules and the cytoskeleton could be linked to the signals that cells obtain from their environment and from inside the cell.
